Energy balance modulates colon tumor growth: Interactive roles of insulin and estrogen

Molecular Carcinogenesis

Volumn 50, Issue 5, 2011, Pages 370-382

  Rondini, Elizabeth A ^a   Harvey, Alison E ^b   Steibel, Juan P ^d   Hursting, Stephen D ^b,c   Fenton, Jenifer I ^a,e  

^a Michigan State University   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d MICHIGAN STATE UNIVERSITY   (United States)

^e MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Adiponectin; Colon cancer; Estrogen; Leptin; Mc38

Indexed keywords

ADIPONECTIN; ESTROGEN; INSULIN; LEPTIN; MITOGEN ACTIVATED PROTEIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CALORIC RESTRICTION; CANCER RISK; CELL PROLIFERATION; COLON TUMOR; COLORECTAL CANCER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIETARY INTAKE; ENERGY BALANCE; ENZYME ACTIVATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; MOUSE; NONHUMAN; OBESITY; OVARIECTOMY; PRIORITY JOURNAL; TUMOR GROWTH;

ANIMALS; BLOTTING, WESTERN; CALORIC RESTRICTION; CELL LINE, TUMOR; CELL PROLIFERATION; COLORECTAL NEOPLASMS; CYTOKINES; DIETARY FATS; ENERGY METABOLISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTROGENS; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HYPOGLYCEMIC AGENTS; INSULIN; LEPTIN; MICE; MICE, INBRED C57BL; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NEOPLASM TRANSPLANTATION; OBESITY; OVARIECTOMY; PHOSPHORYLATION; RANDOM ALLOCATION;

ANIMALIA; MUS;

EID: 79953772541     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20720     Document Type: Article

References (83)

1. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAM 2010; 303: 235-241.
2. World Health Organization. Obesity, overweight fact sheet. Geneva, Switzerland: World Health Organization; 2006.
3. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP). Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 2001; 285: 2486-2497.
4. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: A systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569-578.
5. American Cancer Society. Cancer facts and figures. American Cancer Society; 2009.
6. Dai Z, Xu YC, Niu L. Obesity and colorectal cancer risk: A meta-analysis of cohort studies. World J Gastroenterol 2007; 13: 4199-4206.
7. Ning Y, Wang L, Giovannucci EL. A quantitative analysis of body mass index and colorectal cancer: Findings from 56 observational studies. Obes Rev 2010; 11: 19-30.
8. Larsson SC, Wolk A. Obesity and colon and rectal cancer risk: A meta-analysis of prospective studies. Am J Clin Nutr 2007; 86: 556-565.
9. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: A review and meta-analysis. Am J Med 1999; 106: 574-582.
10. Farquhar C, Marjoribanks J, Lethaby A, Suckling JA, Lamberts Q. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2009; CD004143.
11. Pischon T, Lahmann PH, Boeing H, et al. Body size and risk of colon and rectal cancer in the European prospective investigation into cancer and nutrition (EPIC). J Natl Cancer Inst 2006; 98: 920-931.
12. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-333.
13. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy-scientific review. JAMA 2002; 288: 872-881.
14. McMichael AJ, Potter JD. Reproduction, endogenous and exogenous sex hormones, and colon cancer: A review and hypothesis. J Natl Cancer Inst 1980; 65: 1201-1207.
15. Smirnoff P, Liel Y, Gnainsky J, Shany S, Schwartz B. The protective effect of estrogen against chemically induced murine colon carcinogenesis is associated with decreased CpG island methylation and increased mRNA and protein expression of the colonic vitamin D receptor. Oncol Res 1999; 11: 255-264.
16. Wolf LA, Terry PD, Potter JD, Bostick RM. Do factors related to endogenous and exogenous estrogens modify the relationship between obesity and risk of colorectal adenomas in women? Cancer Epidemiol Biomarkers Prev 2007; 16: 676-683.
17. Kim SE, Shim KN, Jung SA, Yoo K, Moon IH. An association between obesity and the prevalence of colonic adenoma according to age and gender. J Gastroenterol 2007; 42: 616-623.
18. Kennelly R, Kavanagh DO, Hogan AM, Winter DC, Oestrogen and the colon: Potential mechanisms for cancer prevention. Lancet Oncol 2008; 9: 385-391.
19. Campbell-Thompson M, Lynch IJ, Bhardwaj B. Expression of estrogen receptor (ER) subtypes and ERbeta isoforms in colon cancer. Cancer Res 2001; 61: 632-640.
20. Nussler NC, Reinbacher K, Shanny N, et al. Sex-specific differences in the expression levels of estrogen receptor subtypes in colorectal cancer. Gend Med 2008; 5: 209-217.
21. Wada-Hiraike O, Imamov O, Hiraike H, et al. Role of estrogen receptor beta in colonic epithelium. Proc Natl Acad Sci USA 2006; 103: 2959-2964.
22. Maseide K, Kandel RA, Bell RS, et al. Carbonic anhydrase IX as a marker for poor prognosis in soft tissue sarcoma. Clin Cancer Res 2004; 10: 4464-4471.
23. Foley EF, Jazaeri AA, Shupnik MA, Jazaeri O, Rice LW. Selective loss of estrogen receptor beta in malignant human colon. Cancer Res 2000; 60: 245-248.
24. Konstantinopoulos PA, Kominea A, Vandoros G, et al. Oestrogen receptor beta (ER beta) is abundantly expressed in normal colonic mucosa, but declines in colon adenocarcinoma paralleling the tumour's dedifferentiation. Eur J Cancer 2003; 39: 1251-1258.
25. Riant E, Waget A, Cogo H, Arnal JF, Burcelin R, Gourdy P. Estrogens protect against high-fat diet-induced insulin resistance and glucose intolerance in mice. Endocrinology 2009; 150: 2109-2117.
26. Heine PA, Taylor JA, Iwamoto GA, Lubahn DB, Cooke PS. Increased adipose tissue in male and female estrogen receptor-alpha knockout mice. Proc Natl Acad Sci USA 2000; 97: 12729-12734.
27. Ohlsson C, Hellberg N, Parini P, et al. Obesity and disturbed lipoprotein profile in estrogen receptor-alpha-deficient male mice. Biochem Biophys Res Commun 2000; 278: 640-645.
28. Ley CJ, Lees B, Stevenson JC. Sex- and menopause-associated changes in body-fat distribution. Am J Clin Nutr 1992; 55: 950-954.
29. Carr MC. The emergence of the metabolic syndrome with menopause. J Clin Endocrinol Metab 2003; 88: 2404-2411.
30. Giovannucci E. Metabolic syndrome, hyperinsulinemia, and colon cancer: A review. Am J Clin Nutr 2007; 86: s836-s842.
31. Heinz-Erian P, Kessler U, Funk B, Gais P, Kiess W. Identification and in situ localization of the insulin-like growth factor-II/mannose-6-phosphate (IGF-II/M6P) receptor in the rat gastrointestinal tract: Comparison with the IGF-I receptor. Endocrinology 1991; 129: 1769-1778.
32. Remacle-Bonnet MM, Garrouste FL, Heller S, Andre F, Marvaldi JL, Pommier GJ. Insulin-like growth factor-I protects colon cancer cells from death factor-induced apoptosis by potentiating tumor necrosis factor alpha-induced mitogen-activated protein kinase and nuclear factor kappaB signaling pathways. Cancer Res 2000; 60: 2007-2017.
33. Hakam A, Yeatman TJ, Lu L, et al. Expression of insulin-like growth factor-1 receptor in human colorectal cancer. Hum Pathol 1999; 30: 1128-1133.
34. Fenton JI, Hord NG, Lavigne JA, Perkins SN, Hursting SD. Leptin, insulin-like growth factor-1, and insulin-like growth factor-2 are mitogens in ApcMin/+ but not Apc+/+ colonic epithelial cell lines. Cancer Epidemiol Biomarkers Prev 2005; 14: 1646-1652.
35. Koenuma M, Yamori T, Tsuruo T. Insulin and insulin-like growth factor 1 stimulate proliferation of metastatic variants of colon carcinoma 26. Jpn J Cancer Res 1989; 80: 51-58.
36. Bird CL, Ingles SA, Frankl HD, Lee ER, Longnecker MP, Haile RW. Serum lipids and adenomas of the left colon and rectum. Cancer Epidemiol Biomarkers Prev 1996; 5: 607-612.
37. Yamada K, Araki S, Tamura M, et al. Relation of serum total cholesterol, serum triglycerides and fasting plasma glucose to colorectal carcinoma in situ. Int J Epidemiol 1998; 27: 794-798.
38. Komninou D, Ayonote A, Richie JP, Jr., Rigas B. Insulin resistance and its contribution to colon carcinogenesis. Exp Biol Med (Maywood) 2003; 228: 396-405.
39. Pais R, Silaghi H, Silaghi AC, Rusu ML, Dumitrascu DL. Metabolic syndrome and risk of subsequent colorectal cancer. World J Gastroenterol 2009; 15: 5141-5148.
40. Lyon CJ, Law RE, Hsueh WA. Minireview: Adiposity, inflammation, and atherogenesis. Endocrinology 2003; 144: 2195-2200.
41. Juge-Aubry CE, Henrichot E, Meier CA. Adipose tissue: A regulator of inflammation. Best Pract Res Clin Endocrinol Metab 2005; 19: 547-566.
42. Wang XP, Schunck M, Kallen KJ, et al. The interleukin-6 cytokine system regulates epidermal permeability barrier homeostasis. J Invest Dermatol 2004; 123: 124-131.
43. Giraud AS, Jackson C, Menheniott TR, Judd L. Role of trefoil peptides and IL-6 cytokine family signaling in gastric homeostasis. Am J Physiol Gastrointest Liver Physiol 2007; 292: G1-G5.
44. Steensberg A. The role of IL-6 in exercise-induced immune changes and metabolism. Exerc Immunol Rev 2003; 9: 40-47.
45. Gnacinska M, Malgorzewicz S, Stojek M, Lysiak-Szydlowska W, Sworczak K. Role of adipokines in complications related to obesity: A review. Adv Med Sci 2009; 54: 150-157.
46. Kim JH, Bachmann RA, Chen J. Interleukin-6 and insulin resistance. Vitam Horm 2009; 80: 613-633.
47. Rabe K, Lehrke M, Parhofer KG, Broedl UC. Adipokines and insulin resistance. Mol Med 2008; 14: 741-751.
48. Otake S, Takeda H, Fujishima S, et al. Decreased levels of plasma adiponectin associated with increased risk of colorectal cancer. World J Gastroenterol 2010; 16: 1252-1257.
49. Otake S, Takeda H, Suzuki Y, et al. Association of visceral fat accumulation and plasma adiponectin with colorectal adenoma: Evidence for participation of insulin resistance. Clin Cancer Res 2005; 11: 3642-3646.
50. Wei EK, Giovannucci E, Fuchs CS, Willett WC, Mantzoros CS. Low plasma adiponectin levels and risk of colorectal cancer in men: A prospective study. J Natl Cancer Inst 2005; 97: 1688-1694.
51. Yakar S, Nunez NP, Pennisi P, et al. Increased tumor growth in mice with diet-induced obesity: Impact of ovarian hormones. Endocrinology 2006; 147: 5826-5834.
52. Nunez NP, Perkins SN, Smith NC, et al. Obesity accelerates mouse mammary tumor growth in the absence of ovarian hormones. Nutr Cancer 2008; 60: 534-541.
53. Corbett TH, Griswold DP, Jr., Roberts BJ, Peckham JC, Schabel FM, Jr. Tumor induction relationships in development of transplantable cancers of the colon in mice for chemotherapy assays, with a note on carcinogen structure. Cancer Res 1975; 35: 2434-2439.
54. Pajtasz-Piasecka E, Szyda A, Rossowska J, et al. Loss of tumorigenicity of murine colon carcinoma MC38/0 cell line after transduction with a retroviral vector carrying murine IL-12 genes. Folia Biol (Praha) 2004; 50: 7-14.
55. Cui XG, Hwang JTG, Qiu J, Blades NJ, Churchill GA. Improved statistical tests for differential gene expression by shrinking variance components estimates. Biostatistics 2005; 6: 59-75.
56. Storey JD, Tibshirani R. Statistical methods for identifying differentially expressed genes in DNA microarrays. Methods Mol Biol 2003; 224: 149-157.
57. Gentleman RC, Carey VJ, Bates DM, et al. Bioconductor: Open software development for computational biology and bioinformatics. Genome Biol 2004; 5: R80.
58. Misso ML, Murata Y, Boon WC, Jones ME, Britt KL, Simpson ER. Cellular and molecular characterization of the adipose phenotype of the aromatase-deficient mouse. Endocrinology 2003; 144: 1474-1480.
59. Murata Y, Robertson KM, Jones ME, Simpson ER. Effect of estrogen deficiency in the male: The ArKO mouse model. Mol Cell Endocrinol 2002; 193: 7-12.
60. Kamei Y, Suzuki M, Miyazaki H, et al. Ovariectomy in mice decreases lipid metabolism-related gene expression in adipose tissue and skeletal muscle with increased body fat. J Nutr Sci Vitaminol (Tokyo) 2005; 51: 110-117.
61. Hong J, Stubbins RE, Smith RR, Harvey AE, Nunez NP. Differential susceptibility to obesity between male, female and ovariectomized female mice. Nutr J 2009; 8: 11.
62. Ziemke F, Mantzoros CS. Adiponectin in insulin resistance: Lessons from translational research. Am J Clin Nutr 2010; 91: 258S-261S.
63. Goktas S, Yilmaz MI, Caglar K, Sonmez A, Kilic S, Bedir S. Prostate cancer and adiponectin. Urology 2005; 65: 1168-1172.
64. Chen DC, Chung YF, Yeh YT, et al. Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett 2006; 237: 109-114.
65. Dal Maso L, Augustin LS, Karalis A, et al. Circulating adiponectin and endometrial cancer risk. J Clin Endocrinol Metab 2004; 89: 1160-1163.
66. Ishikawa M, Kitayama J, Kazama S, Hiramatsu T, Hatano K, Nagawa H. Plasma adiponectin and gastric cancer. Clin Cancer Res 2005; 11: 466-472.
67. Ruhl CE, Harris TB, Ding JZ, et al. Body mass index and serum leptin concentration independently estimate percentage body fat in older adults. Am J Clin Nutr 2007; 85: 1121-1126.
68. Stattin P, Palmqvist R, Soderberg S, et al. Plasma leptin and colorectal cancer risk: A prospective study in Northern Sweden. Oncol Rep 2003; 10: 2015-2021.
69. Cong JC, Dai XW, Shen MY, et al. Expression of obesity hormone leptin in human colorectal cancer. Chin J Cancer Res 2009; 21: 142-146.
70. Hardwick JCH, Van den Brink GR, Offerhaus GJ, Van Deventer SJH, Peppelenbosch MP. Leptin is a growth factor for colonic epithelial cells. Gastroenterology 2001; 121: 79-90.
71. Birmingham JM, Busik JV, Hansen-Smith FM, Fenton JI. Novel mechanism for obesity-induced colon cancer progression. Carcinogenesis 2009; 30: 690-697.
72. Pisani P. Hyper-insulinaemia and cancer, meta-analyses of epidemiological studies. Arch Physiol Biochem 2008; 114: 63-70.
73. Trevisan M, Liu J, Muti P, et al. Markers of insulin resistance and colorectal cancer mortality. Cancer Epidemiol Biomarkers Prev 2001; 10: 937-941.
74. Siddiqui AA, Spechler SJ, Huerta S, Dredar S, Little BB, Cryer B. Elevated HbA1c is an independent predictor of aggressive clinical behavior in patients with colorectal cancer: A case-control study. Dig Dis Sci 2008; 53: 2486-2494.
75. Motylewska E, Lawnicka H, Melen-Mucha G. Oestradiol and tamoxifen inhibit murine Colon 38 cancer growth and increase the cytotoxic effect of fluorouracil. Endokrynol Pol 2007; 58: 426-434.
76. Crowell JA, Steele VE, Fay JR. Targeting the AKT protein kinase for cancer chemoprevention. Mol Cancer Ther 2007; 6: 2139-2148.
77. Hursting SD, Berger NA. Energy balance, host-related factors, and cancer progression. J Clin Oncol 2010; 28: 4058-4065.
78. Kalaany NY, Sabatini DM. Tumours with PI3K activation are resistant to dietary restriction. Nature 2009; 458: 725-731.
79. Chalvatzas N, Dafopoulos K, Kosmas G, Kallitsaris A, Pournaras S, Messinis IE. Effect of ovarian hormones on serum adiponectin and resistin concentrations. Fertil Steril 2009; 91: 1189-1194.
80. Horenburg S, Fischer-Posovszky P, Debatin KM, Wabitsch M. Influence of sex hormones on adiponectin expression in human adipocytes. Horm Metab Res 2008; 40: 779-786.
81. Leung KC, Xu A, Craig ME, Martin A, Lam KS, O'Sullivan AJ. Adiponectin isoform distribution in women-Relationship to female sex steroids and insulin sensitivity. Metabolism 2009; 58: 239-245.
82. Salpeter SR, Walsh JM, Ormiston TM, Greyber E, Buckley NS, Salpeter EE. Meta-analysis: Effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. Diabetes Obes Metab 2006; 8: 538-554.
83. Bryzgalova G, Lundholm L, Portwood N, et al. Mechanisms of antidiabetogenic and body weight-lowering effects of estrogen in high-fat diet-fed mice. Am J Physiol Endocrinol Metab 2008; 295: E904-E912.